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Abstract 
Nicotine addiction is considered to be the main preventable cause of death worldwide. While 
growing evidence indicates that the neurohypophysial peptide oxytocin can modulate the 
addictive properties of several abused drugs, the regulation of the oxytocinergic system 
following nicotine administration has so far received little attention. Here, we examined the 
effects of long-term nicotine or saline administration on the central oxytocinergic system using 
[125I]OVTA autoradiographic binding in mouse brain. Male, 7-week old C57BL6J mice were 
treated with either nicotine (7.8 mg/kg daily; rate of 0.5 μl per hour) or saline for a period of 14-
days via osmotic minipumps. Chronic nicotine administration induced a marked region-specific 
upregulation of the oxytocin receptor binding in the amygdala, a brain region involved in stress 
and emotional regulation. These results provide direct evidence for nicotine-induced 
neuroadaptations in the oxytocinergic system, which may be involved in the modulation of 
nicotine-seeking as well as emotional consequence of chronic drug use. 
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Highlights 
 Nicotine administration increases amygdalar oxytocin receptor binding 
 Chronic nicotine does not alter oxytocin receptor binding in the striatum 
 Oxytocin may be a potential target for the treatment of nicotine addiction 
Introduction 
Cigarette smoking is considered the main preventable cause of death worldwide [1]. While there 
is evidence suggesting that nicotine may exert antidepressant [2-5] and anxiolytic [6] effects, 
chronic nicotine use has been also associated with severe depression symptoms [7-9] and 
anxiety, which persist following abstinence [10,11]. This negative affective state following 
nicotine cessation might contribute to relapse [12]. Although there are currently numerous 
therapeutic agents and cognitive behavioural interventions for smoking cessation that are 
considered  beneficial for the treatment of nicotine addiction, none of these therapeutic strategies 
has been shown to effectively prevent relapse to nicotine-seeking following abstinence [13]. In 
fact, among the 40% of smokers undergoing smoking-cessation interventions, only a small 
percentage of 4% achieve a long-term abstinence for 6 to 12 months [14]. Therefore, 
development of an optimal treatment for the effective treatment and prevention of nicotine 
use and relapse following abstinence requires further understanding of the mechanisms 
contributing to nicotine long-term abuse, which might be associated with the emergence of 
emotional impairment during withdrawal. 
Emerging evidence indicates the involvement of the oxytocinergic system in drug addiction 
processes [15-17]. In particular, chronic administration of addictive substances including cocaine 
[18,19], methamphetamine [20], opioids [21] and alcohol [22] have been shown to induce 
marked alterations in the oxytocin (OT) system in the brain, which might be involved in the 
modulation of the emotional consequences of chronic drug use. Indeed, recent evidence supports 
an association between oxytocinergic deficiency and the negative emotional consequences of 
drug addiction, including depression, anxiety and social deficits [21]. OT-producing neurons 
located in the hypothalamus also project to several brain regions involved in drug-seeking 
behaviour as well as emotional regulation, including the septum and amygdala, where oxytocin 
receptors (OTR) are expressed [23].Few previous studies also demonstrated a role for OT in the 
modulation of nicotine addiction processes. In particular, acute intravenous administration of 
nicotine has been shown to decrease OT content in the pituitary of rats [24], and systemic 
administration of OT abolished physical somatic symptoms of nicotine withdrawal in rats [25]. 
Overall, although these studies clearly support the involvement of OT in nicotine addiction, the 
effects of chronic nicotine administration on the central oxytocinergic system remains largely 
unknown. 
Based on the evidence implicating the OT neuropeptidergic system in addictive-related 
behaviours, we hypothesized that chronic nicotine administration might also induce alterations in 
the central oxytocinergic system. This is the first study to investigate the effects of chronic 
nicotine treatment on oxytocin receptor binding with the use of autoradiographic binding.  
  
Materials and Methods 
Animals and chronic nicotine administration paradigm 
Male C57BL/6J mice (seven-week old, Charles River Laboratories, Kingston, UK), were 
individually housed in a temperature-controlled environment with a 12:12-hour light/dark cycle 
(lights on at 06:00).  Food and water were available ad libitum. Mice were given seven days to 
acclimatize to their new environment and were handled daily by the experimenter. Mice were 
treated with a nicotine administration paradigm as described previously [26]. Briefly, saline or 
nicotine hydrogen salt (7.8 mg/kg/day; Sigma-Aldrich, UK) were administered via osmotic mini-
pumps (ALZET®2002 model, Charles River, UK). For minipump implantation, mice were 
anaesthetised using an isoflurane/oxygen vapour mixture (3.5%–4.5%; Isoflo, Abbott 
Laboratories Ltd, UK). A single incision along the midline of the back of each animal was made 
and osmotic mini-pumps were placed in parallel position to the spine. The flow operator was 
pointing away from the incision site. Nicotine was delivered for a period of 14 days at the daily 
dose of 7.8 mg/kg (free-base weight), at a rate of 0.5 μl per hour. This dose has been shown to 
induce blood nicotine levels comparable to the values measured in human smokers [26]. 
All animal care and experimental procedures complied with protocols approved by the 
University of Surrey Animal Welfare and Ethical Review Body and by the UK Home Office 
under Animals (Scientific Procedures) Act 1986. Mice were randomly assigned to two different 
drug-administration groups; control saline-treated group and chronic nicotine-treated group.  
  
OTR autoradiography 
OTR binding was carried out on sections from 14-day saline- and nicotine-treated mice as 
previously described [20].  Total binding was determined by incubating sections with 50 pM 
125I-ornithine vasotocin (OVTA) for 1 hour in an incubation buffer medium containing 50mM 
Tris-HCl, 10mM MgCl2, 1mM ethylenediaminetetraacetic acid (EDTA), 0.1 % w/v bovine 
serum albumin, and 0.05 % w/v bacitracin (Sigma-Aldrich, Poole, UK, pH 7.4 at room 
temperature). Adjacent sections were incubated with [125I]-OVTA (50 pM) in the presence of 
50μM unlabelled (Thr4,Gly7)-oxytocin (Bachem, Germany), to determine non-specific binding 
(NSB). Slides were apposed to Kodak MR-1 films (Sigma-Aldrich, UK) in Hypercassettes with 
autoradiographic [14C] microscales of known radioactive concentration (GE Healthcare 
Life Sciences, Amersham, U.K.) for 3 days. Films were developed in a 50% Kodak D19 
developer solution (Sigma-Aldrich, Poole, UK) and analyzed using MCID image analyzer 
(Image Research, Ontario, Canada).  
Statistical Analysis 
All values were expressed as mean ± SEM. For the analysis of regional OTR binding, two-way 
ANOVA was performed for factors ‘treatment (saline/nicotine)’ and ‘brain region’ at different 
bregma levels. Bonferroni post-hoc test was used when ANOVA reached significance (i.e., 
p<0.05). All statistical analyses were performed using Statistica 8.0 (Statsoft Inc., France). 
  
Results 
High levels of OTR binding (0.97-1.15 fmol/mg tissue) were observed within the olfactory 
nuclei, medium binding levels (0.28-0.68 fmol/mg tissue) were identified within the mediolateral 
septum, ventral limb of the diagonal band of Broca, amygdala and hypothalamus, while low 
levels of binding (0.07-0.17 fmol/mg tissue) were observed in striatal regions (i.e., nucleus 
accumbens, caudate putamen and olfactory tubercle) as well as the thalamus (Figure 1A-E).  
Olfactory nuclei: Two-way ANOVA showed a significant effect of ‘brain region’ 
(F[2,24] = 7.37, p < 0.01), but no ‘treatment’ (F[1,24] = 0.30, p > 0.05) or ‘treatment’ x ‘brain 
region’ interaction  effect (F[2,24] = 0.01, p > 0.05).  
Striatum: Two-way ANOVA revealed a significant effect of ‘brain region’ 
(F[2,24] = 4.48, p < 0.05), but no ‘treatment’ (F[1,24] = 0.26, p > 0.05) or ‘treatment’ x ‘brain 
region’ interaction effect (F[2,24] = 0.06, p > 0.05). 
Septum: Two-way ANOVA revealed a significant effect of ‘brain region’ 
(F[2,24] = 10.06, p < 0.001), but no ‘treatment’ (F[1,24] = 0.64, p > 0.05) or ‘treatment’ x ‘brain 
region’ interaction  effect (F[2,24] = 0.09, p > 0.05).  
Forebrain: Two-way ANOVA revealed a significant effect of ‘brain region’ 
(F[3,27] = 53.50, p < 0.001) and ‘treatment’ x ‘brain region’ interaction effect 
(F[3,27] = 3.40, p < 0.05). Bonferroni’s post-hoc comparison test showed a significant, 46% 
increase of OTR binding in the amygdala following nicotine treatment (p<0.01). No effects of 
nicotine administration on the OTR binding were observed in the hippocampus, thalamus, or 
hypothalamus (p>0.05). 
 
Discussion 
The present study demonstrated, for the first time, a region-specific alteration of the OTR 
binding in the brain of mice treated with a chronic nicotine administration paradigm. This up-
regulation of the OTR was specifically localized in the amygdala, a region involved in stress and 
emotional regulation [27,28]. Therefore, this oxytocinergic system alteration may be involved in 
the modulation of long-term behavioural adaptations induced by chronic nicotine exposure. 
Expression and distribution of the OTR observed in the current study is in line with previous 
published data in mice [e.g. 20,29]. Although alterations of the endogenous oxytocin system 
have been previously demonstrated following acute or chronic alcohol [30], cocaine [18,19,31], 
methamphetamine [20], 3,4-methylenedioxymethamphetamine (MDMA) [32] and morphine 
[21,33,34] administration in the brain of rodents, this is the first study to report central 
oxytocinergic neuroadaptations following chronic nicotine administration.  The up-regulation of 
OTR binding in the amygdala observed in the present study, is in line with studies investigating 
the effects of chronic opioid, cocaine and methamphetamine administration on the central 
oxytocinergic system [19,20,35], indicating a possible common mechanism of action of several 
drugs of abuse through the modulation of the amygdalar OTR. 
The role of this nicotine-induced increase in OTR binding is yet to be determined. However, 
given the involvement of the amygdala in a number of facets of emotional regulation [27] and 
social cognition [36], we can postulate that the alterations observed in this study might reflect 
neuroadaptations of the OT system in response to emotional and cognitive impairments induced 
by chronic nicotine. Indeed, chronic nicotine administration has been shown to induce emotional 
deficits, including depression and anxiety [10]. This hypothesis is further supported by findings 
demonstrating that the anxiolytic, antidepressant and stress-relieving properties of OT to be at 
least partly modulated by the amygdala [37]. 
Nicotine administration has been also shown to exert cognition-enhancing effects [38]. Since 
oxytocin is also considered as a key mediator of social cognition in humans [39] and this effect 
has been postulated to specifically involve the OT system in the Amy [40], the OTR up-
regulation observed here might also be associated with a possible nicotine regulation of 
cognition through an OTR-dependent mechanism. However, this hypothesis needs to be further 
investigated. 
Importantly, alterations of OTR in the amygdala have been previously associated with a hypo-
oxytocinergic tone in the brain. In particular, chronic morphine administration and withdrawal 
induced a marked decrease in the hypothalamic OT levels, concomitant with a rebound increase 
of the OTR in the amygdala [21]. Considering these findings and since an increase in OT peptide 
levels or administration of an OTR agonist induces rapid OTR desensitization, clathrin-
dependent internalisation and subsequent downregulation of the receptors [41], we can speculate 
that the up-regulation of OTR in the amygdala is a rebound consequence of a possible reduction 
of OT levels in the brain following chronic nicotine administration. Indeed, there is evidence for 
a reduced oxytocinergic tone following nicotine administration, as acute nicotine was shown to 
diminish OT levels in the pituitary of rats [24]. 
In conclusion, this is the first study to demonstrate direct brain region-specific alterations in the 
amygdalar OTR following nicotine administration in mice. This study suggests the alterations of 
OTR as one possible mechanism underlying behavioural and neurochemical alterations observed 
in nicotine addiction. 
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Figure Legend 
Figure 1: Oxytocin receptor (OTR) binding in the brain of mice following long-term nicotine 
administration. C57BL/6J mice were treated for fourteen days with either saline or nicotine via 
osmotic minipumps. (A) Representative autoradiograms of 50 pM [125I]-ornithine vasotocin 
analogue binding to OTR in coronal brain sections at the level of the olfactory nuclei (row 1), 
striatum (row 2), septum (row 3) and forebrain (row 4). Binding levels are represented using a 
pseudo-colour interpretation of black and white film images in fmol/mg of tissue equivalent. 
Quantitative OTR binding levels at the level of (B) olfactory nuclei, (C) striatum, (D) septum 
and (E) forebrain, where OTRs are expressed. Data are expressed as mean ± SEM (n=4-6 per 
treatment group). **p<0.01 vs saline control. Abbreviations: Acb, nucleus accumbens; Amy, 
amygdala; AOL, anterior olfactory nucleus-lateral; AOM, anterior olfactory nucleus-medial; 
AOV, anterior olfactory nucleus-ventral; CPu, caudate putamen; Hip, hippocampus; Hyp, 
hypothalamus; LS, lateral septum; MS, medial septum; Th, thalamus; Tu, olfactory tubercle; 
VDB, vertical limb of diagonal band of Broca. 
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